Consumers Pay As Drug Firms Fight over Generics. / Julie Appleby and Jayne O'Donnell.
by Appleby, Julie; SIRS Publishing, Inc.
Material type:
BookSeries: SIRS Enduring Issues 2003Article 74Business. Publisher: Gannett News Service (Syndicate), 2002ISSN: 1522-3191;.Subject(s): Consumer protection | Drugs -- Prices | Generic drugs | Patents | Paxil | Pharmaceutical industryDDC classification: 050 Summary: "Drug companies are finding it to their advantage to file additional patents on existing drugs. Such moves can keep lower-cost generics off the market for years." (USA TODAY) This article suggests that drug companies are filing for unnecessary patent extensions "to delay rivals as long as possible, knowing that prices and their own market share for top-selling products can drop by half or more once generics hit the market.".
| Item type | Current location | Call number | Status | Date due |
|---|---|---|---|---|
Books
|
High School - old - to delete | REF SIRS 2003 Bus74 (Browse shelf) | Available |
Browsing High School - old - to delete Shelves Close shelf browser
| No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
| REF SIRS 2003 Bus73 Intrigue, Lust and Merchandising. / | REF SIRS 2003 Bus73 A Word from Our Sponsor? He's Here Now.. / | REF SIRS 2003 Bus74 Counter Move. / | REF SIRS 2003 Bus74 Consumers Pay As Drug Firms Fight over Generics. / | REF SIRS 2003 Bus75 Children, Entertainment, and Marketing. / | REF SIRS 2003 Bus76 Living Ever Larger. / | REF SIRS 2003 Bus77 Insurance After 9/11. / |
Articles Contained in SIRS Enduring Issues 2003.
Originally Published: Consumers Pay As Drug Firms Fight over Generics, June 6, 2002; pp. 1A-2A.
"Drug companies are finding it to their advantage to file additional patents on existing drugs. Such moves can keep lower-cost generics off the market for years." (USA TODAY) This article suggests that drug companies are filing for unnecessary patent extensions "to delay rivals as long as possible, knowing that prices and their own market share for top-selling products can drop by half or more once generics hit the market.".
Records created from non-MARC resource.
There are no comments for this item.